bioRxiv · 10.64898/2026.03.19.712819
Expression of amyloid-β antibody via AAV of CNS tropism alleviates Alzheimer's disease in mice
Abstract
Alzheimers disease (AD), the leading cause of dementia, affects over 33 million people worldwide, with pathogenesis tied to amyloid-{beta} (A{beta}) accumulation. Although anti-A{beta} monoclonal antibodies have shown clinical benefits, they often cause side effects including amyloid-related imaging abnormalities and brain microhemorrhage, especially in APOE E4 allele carriers. Here we used PHP.eB serotype adeno-associated virus (AAV), a vector with enhanced central nervous system (CNS) tropism, to deliver an A{beta} antibody expression vector (AAV-LEC) into the CNS of APP/PS1 and 5xFAD mice intravenously. The AAV-LEC-mediated expression of anti-A{beta} antibodies in the CNS significantly reduced the number and size of A{beta} plaques at various stages in both APP/PS1 and 5xFAD mice, alongside improved spatial learning and memory. It also reversed abnormal glial activation with reduced disease-associated microglia and astrocytes, and restored oligodendrocyte differentiation and myelin formation. No brain microhemorrhage or liver damage was detected following the AAV-antibody treatment. Thus, this AAV-mediated strategy offers a promising, convenient and safe AD therapeutic approach in the future.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Dai, Z.-M., Min Jiang, M., Yin, W., Wang, Z., Zhu, X.-J., Qiu, M.. 2026-03-20. Expression of amyloid-β antibody via AAV of CNS tropism alleviates Alzheimer's disease in mice. https://doi.org/10.64898/2026.03.19.712819
Cite the original work for its findings. Save a collection to share your selection of sources.